Back to Agenda
Session 3 Track 2: Advances in Oligonucleotide Delivery
Session Chair(s)
Arthur A. Levin, PhD
Senior Consultant
Levin BioScience, United States
Philip Gatti, PhD
Pharmacologist
FDA, United States
This session will explore three novel areas of delivery. Oral, lipid conjugated siRNA-dimers and synthetic exosomes. The goal of the session is to consider a small fraction of the diversity of technologies which can be utilized to overcome the challenges of moving highly water-soluble nucleic acid therapeutics through cell membranes to produce pharmacologic activity.
This session should address key questions like- how broadly applicable is this technology across the different modalities of oligonucleotide therapeutics? Does this modality enhance the therapeutic index of a compound? Is this delivery modality amenable to multiple cell and tissue types?
Speaker(s)
Exosome Mediated Genetic Reprogramming of Tumor Associated Macrophages by exoASO-STAT6
Sriram Sathyanarayanan, PhD, MSc
Codiak Biosciences , United States
Chief Scientific Officer
Branched siRNA for Broad and Durable Target Silencing in the CNS
Stefan McDonough, PhD
Atalanta, United States
Vice President, Neuroscience
Recent Efforts in the Oral Delivery of GalNAc-Conjugated ASOs
Scott Henry, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Nonclinical Development
Have an account?